4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Provided By GlobeNewswire

Last update: Feb 28, 2025

EMERYVILLE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported full year 2024 financial results, provided operational highlights and outlined expected upcoming milestones.